CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biotie Therapies Corp. (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biotie Therapies Corp. (OLD)
Joukahaisenkatu 6
Phone: +358 22748900p:+358 22748900 TURKU, 20520  Finland Fax: +358 22748910f:+358 22748910

This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Biotie Therapies Corp is a Finland-based drug development company focused on developing products for neurodegenerative and psychiatric disorders. The Company’s lead market product is Selincro (nalmefene), a therapeutic for alcohol dependence that is rolled out across Europe by its partner Lundbeck. Its product pipeline includes tozadenant, a therapeutic for Parkinson’s disease that is in Phase Three development; and two additional compounds in Phase Two development that treat cognitive disorders, namely: SYN120, an orally administered compound therapeutic for Parkinson’s disease dementia, and BTT1023, a human monoclonal antibody targeting compound therapeutic for primary sclerosing cholangitis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201612/31/2015Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board RonCohen 60 5/3/2016 5/3/2016
Chief Executive Officer AnteroKallio 56 7/1/2016
Chief Financial Officer KristianRantala 40 7/1/2016 11/1/2012
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Biotie Therapies AG
Biotie Therapies Corp.
Biotie Therapies Holding AG
BTT1V
Synosia Therapeutics
Synosia Therapeutics Holding AG

General Information
Stock Exchange: HEL
Fax Number: +358 22748910


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 7, 2021